目次

Table of Contents

Executive Summary
Market overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Five forces summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Type
Market segments
Comparison by Type
Second-generation ALK inhibitors - Market size and forecast 2020-2025
First-generation ALK inhibitors - Market size and forecast 2020-2025
Third-generation ALK inhibitors - Market size and forecast 2020-2025
Market opportunity by Type

Customer Landscape

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity by geography
Market drivers
Market challenges
Market trends

Vendor Landscape
Overview
Vendor landscape
Landscape disruption

Vendor Analysis
Vendors covered
Market positioning of vendors
Betta Pharmaceuticals Co. Ltd.
Bio-Techne Corp.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
F. Hoffmann-La Roche Ltd.
Helsinn Healthcare SA
Merck KGaA
Novartis AG
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.
Turning Point Therapeutics Inc.

Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Type - Market share 2020-2025 (%)
22: Comparison by Type
23: Second-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
24: Second-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
25: First-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
26: First-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
27: Third-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
28: Third-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
29: Market opportunity by Type
30: Customer landscape
31: Market share by geography 2020-2025 (%)
32: Geographic comparison
33: North America - Market size and forecast 2020-2025 ($ million)
34: North America - Year-over-year growth 2020-2025 (%)
35: Europe - Market size and forecast 2020-2025 ($ million)
36: Europe - Year-over-year growth 2020-2025 (%)
37: Asia - Market size and forecast 2020-2025 ($ million)
38: Asia - Year-over-year growth 2020-2025 (%)
39: ROW - Market size and forecast 2020-2025 ($ million)
40: ROW - Year-over-year growth 2020-2025 (%)
41: Key leading countries
42: Market opportunity by geography ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: Betta Pharmaceuticals Co. Ltd. - Overview
50: Betta Pharmaceuticals Co. Ltd. - Product and service
51: Betta Pharmaceuticals Co. Ltd. - Key offerings
52: Betta Pharmaceuticals Co. Ltd. - Key customers
53: Betta Pharmaceuticals Co. Ltd. - Segment focus
54: Bio-Techne Corp. - Overview
55: Bio-Techne Corp. - Business segments
56: Bio-Techne Corp. - Key offerings
57: Bio-Techne Corp. - Key customers
58: Bio-Techne Corp. - Segment focus
59: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Overview
60: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Product and service
61: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Key offerings
62: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Key customers
63: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Segment focus
64: F. Hoffmann-La Roche Ltd. - Overview
65: F. Hoffmann-La Roche Ltd. - Business segments
66: F. Hoffmann-La Roche Ltd. - Key offerings
67: F. Hoffmann-La Roche Ltd. - Key customers
68: F. Hoffmann-La Roche Ltd. - Segment focus
69: Helsinn Healthcare SA - Overview
70: Helsinn Healthcare SA - Product and service
71: Helsinn Healthcare SA - Key offerings
72: Helsinn Healthcare SA - Key customers
73: Helsinn Healthcare SA - Segment focus
74: Merck KGaA - Overview
75: Merck KGaA - Business segments
76: Merck KGaA - Key offerings
77: Merck KGaA - Key customers
78: Merck KGaA - Segment focus
79: Novartis AG - Overview
80: Novartis AG - Business segments
81: Novartis AG - Key offerings
82: Novartis AG - Key customers
83: Novartis AG - Segment focus
84: Pfizer Inc. - Overview
85: Pfizer Inc. - Business segments
86: Pfizer Inc. - Key offerings
87: Pfizer Inc. - Key customers
88: Pfizer Inc. - Segment focus
89: Takeda Pharmaceutical Co. Ltd. - Overview
90: Takeda Pharmaceutical Co. Ltd. - Product and service
91: Takeda Pharmaceutical Co. Ltd. - Key offerings
92: Takeda Pharmaceutical Co. Ltd. - Key customers
93: Takeda Pharmaceutical Co. Ltd. - Segment focus
94: Turning Point Therapeutics Inc. - Overview
95: Turning Point Therapeutics Inc. - Product and service
96: Turning Point Therapeutics Inc. - Key offerings
97: Turning Point Therapeutics Inc. - Key customers
98: Turning Point Therapeutics Inc. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations